Holen Sie sich die Stockscreener-App
9.65
2.66%
0.25
Handel nachbörslich:
9.84
0.19
+1.97%
Schlusskurs vom Vortag:
$9.40
Offen:
$9.94
24-Stunden-Volumen:
175.61K
Relative Volume:
3.77
Marktkapitalisierung:
$157.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.82M
KGV:
-0.3771
EPS:
-25.5891
Netto-Cashflow:
$-66.04M
1W Leistung:
+2.99%
1M Leistung:
+19.43%
6M Leistung:
+25.49%
1J Leistung:
+113.02%
1-Tages-Spanne:
$9.40
$10.00
1-Wochen-Bereich:
$8.51
$10.00
52-Wochen-Spanne:
$3.70
$10.75
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Firmenname
Elicio Therapeutics Inc
Sektor
Branche
Telefon
(857) 209-0050
Adresse
451 D STREET, 5TH FLOOR, BOSTON
Vergleichen Sie ELTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
9.65 | 138.37M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Elicio Therapeutics Inc Aktie (ELTX) Neueste Nachrichten
Is it too late to sell Elicio Therapeutics Inc.July 2025 Rallies & Long Hold Capital Preservation Plans - Newser
Can technical indicators confirm Elicio Therapeutics Inc.’s reversal2025 Retail Activity & Long-Term Growth Stock Strategies - Newser
Why Elicio Therapeutics Inc. is moving todayDollar Strength & Long-Term Growth Portfolio Plans - Newser
News impact scoring models applied to Elicio Therapeutics Inc.Profitable Trading Blueprint with Entry Zones - Newser
What to expect from Elicio Therapeutics Inc. in the next 30 daysFree Opportunity Map for Daily Stock Trading - Newser
Visual trend scoring systems applied to Elicio Therapeutics Inc.2025 Retail Activity & High Accuracy Trade Signal Alerts - Newser
Elicio Therapeutics Announces Publication of ELI-002 - GlobeNewswire
Can trapped investors hope for a rebound in Elicio Therapeutics Inc.Free Portfolio Diversification Stock Ideas - Newser
Amplify Energy Corp. shares rise 4.69% intraday after Elicio Therapeutics published positive clinical trial results for ELI-002. - AInvest
BlinkRx’s Ties to Donald Trump Jr. Questioned Amid Pfizer and Elicio Therapeutics’ Cancer Research Updates - geneonline.com
BostonGene's AI-Powered Oncology Platform Achieves Landmark Validation in Study - AInvest
Elicio Therapeutics Publishes Promising Phase 1 Study Data - TipRanks
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients - GlobeNewswire Inc.
Evaluating Elicio Therapeutics Inc. with trendline analysisPredictable Return Plan with Entry Guidance - Newser
Chart based analysis of Elicio Therapeutics Inc. trendsFree Risk Controlled Short Term Trade Plans - Newser
Analyzing Elicio Therapeutics Inc. with multi timeframe chartsTrading Volume Anomaly Summary and Insight - Newser
What does recent volatility data suggest for Elicio Therapeutics Inc.Risk Balanced Picks for Safer Trading - Newser
What makes Elicio Therapeutics Inc. stock price move sharplyNext Day Momentum Stock Forecasting Report - Newser
Elicio Therapeutics Inc. stock outlook for YEAROversold Opportunity Scanner with RSI Data - Newser
Elicio Therapeutics Reports Q2 2025 Financial Results - TipRanks
Elicio Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
What recovery options are there for Elicio Therapeutics Inc.Free Market Entry and Exit Point Tips - Newser
Analyzing recovery setups for Elicio Therapeutics Inc. investorsFree Real Market Momentum Signal Generator - Newser
Market reaction to Elicio Therapeutics Inc.’s recent newsTechnical Trade Plan with Entry Checklist - Newser
Is Elicio Therapeutics Inc. meeting your algorithmic filter criteriaFree Triple Digit Return Stock Predictions - Newser
Applying chart zones and confluence areas to Elicio Therapeutics Inc.Free AI Based High Gain Watchlist Scanner - Newser
Is Elicio Therapeutics Inc. stock risky to hold nowFlash Gain Trade Picks - mustnews.co.kr
Elicio Therapeutics Inc. Reaches Critical Trendline SupportBuy Signal Based on Chart Analysis Confirmed - metal.it
Using Bollinger Bands to evaluate Elicio Therapeutics Inc.High Yield Watchlist with Filtered Picks - Newser
How hedge fund analytics apply to Elicio Therapeutics Inc. stockFree Sector Based Breakout Stock Forecast - Newser
Elicio (ELTX) Q2 Loss Beats Estimates - AOL.com
Elicio Therapeutics Q2 Results: Net Loss Beats Estimates, R&D Spending Down - AInvest
Predicting Elicio Therapeutics Inc. trend using moving averagesTechnical Trend Forecast for Investors - Newser
Elicio Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Key External Factors That Drive Elicio Therapeutics Inc. Stock Price MovementsDaily Pick Forecast with Entry Zones - Newser
Elicio Therapeutics (ELTX): Clinical Progress Outpaces Financial Losses - AInvest
Elicio Therapeutics Reports Q2 GAAP EPS of -$0.66, Expects Cash to Support Operations into Q1 2026 - AInvest
JonesTrading Sticks to Their Buy Rating for Elicio Therapeutics (ELTX) - The Globe and Mail
Elicio Therapeutics Extends Cash Runway And Advances Cancer Trial - Finimize
Elicio Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Finanzdaten der Elicio Therapeutics Inc-Aktie (ELTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):